Skip to main content

REVELATION BIOSCIENCES, INC.

corporate_fare Company Profile

REVELATION BIOSCIENCES, INC.

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed REVB - Latest Insights

REVB
Mar 30, 2026, 9:00 AM EDT
Source: Access Newswire
Importance Score:
8
Revelation Biosciences Reports Positive PRIME Study Data for Gemini in CKD, Plans Pivotal AKI Trial
Sentiment: Positive
View Wiseek Article
REVB
Mar 19, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
7
Stockholders Approve Significant Dilution for Existing Warrants, Enabling Future Capital Raises
Sentiment: Negative
View Wiseek Article
REVB
Feb 26, 2026, 4:25 PM EST
Filing Type: 8-K
Importance Score:
8
Revelation Biosciences Extends Cash Runway, Reports Positive Clinical Data & FDA Agreement Amidst Going Concern
Sentiment: Positive
View Wiseek Article
REVB
Feb 26, 2026, 4:06 PM EST
Filing Type: 10-K
Importance Score:
9
Annual Report Reveals Going Concern, Heavy Dilution, and Imminent Nasdaq Delisting Risk
Sentiment: Negative
View Wiseek Article
REVB
Feb 17, 2026, 12:35 PM EST
Filing Type: DEF 14A
Importance Score:
8
Shareholders to Vote on Massive Dilution from Class J Warrants
Sentiment: Negative
View Wiseek Article
REVB
Feb 11, 2026, 5:30 PM EST
Filing Type: 424B3
Importance Score:
9
Revelation Biosciences Registers 4.27M Shares for Resale, Posing Significant Dilution Risk
Sentiment: Negative
View Wiseek Article
REVB
Feb 06, 2026, 4:32 PM EST
Filing Type: PRE 14A
Importance Score:
8
Revelation Biosciences Seeks Shareholder Approval for Highly Dilutive Warrant Issuance to Fund Clinical Trials
Sentiment: Negative
View Wiseek Article
REVB
Jan 30, 2026, 4:05 PM EST
Filing Type: S-3
Importance Score:
9
Revelation Biosciences Registers 4.27M Shares for Resale, Signaling Massive Potential Dilution
Sentiment: Negative
View Wiseek Article
REVB
Jan 28, 2026, 6:46 PM EST
Filing Type: 8-K
Importance Score:
8
Revelation Biosciences Secures $7.3M from Warrant Exercises, Issues New Warrants
Sentiment: Positive
View Wiseek Article
REVB
Jan 21, 2026, 7:01 PM EST
Filing Type: 8-K
Importance Score:
9
Revelation Biosciences Secures FDA Agreement for Gemini AKI Approval Pathway
Sentiment: Positive
View Wiseek Article